Inkretinek és inkretinhatású vércukorcsö kkentok pleiotrop tulajdonságai

Translated title of the contribution: Pleiotropic effects of incretins and antidiabetics with incretine mechanism

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes. In addition to the antidiabetic properties more attention is paid to their favourable pleiotropic effects independent from the blood glucose lowering such as cardio-, vaso- and renoprotectiv, blood pressure lowering effects, as well as beneficial changes on blood lipid values and hepatic steatosis. These preferential changes prevail in slightly different way when incretin mimetics applied and dipeptidyl peptidase-4 inhibitors, furthermore, prolonged action of peptides metabolised by this enzyme may serve additional benefits in this latter mentioned group. The article overviews the currently known most important pleiotropic effects of incretins from the point of view of cardiorenal risk accompanying type 2 diabetes. Orv. Hetil., 2013, 154, 248-255.

Original languageHungarian
Pages (from-to)248-255
Number of pages8
JournalOrvosi Hetilap
Volume154
Issue number7
DOIs
Publication statusPublished - 2013

Fingerprint

Incretins
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Blood Glucose
Dipeptidyl-Peptidase IV Inhibitors
Peptides
Glucagon-Like Peptide 1
Pharmacology
Blood Pressure
Lipids
Glucose
Liver
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inkretinek és inkretinhatású vércukorcsö kkentok pleiotrop tulajdonságai. / Winkler, G.

In: Orvosi Hetilap, Vol. 154, No. 7, 2013, p. 248-255.

Research output: Contribution to journalArticle

@article{4fe6add4cabf4703aa7e13bb7ec0e0ac,
title = "Inkretinek {\'e}s inkretinhat{\'a}s{\'u} v{\'e}rcukorcs{\"o} kkentok pleiotrop tulajdons{\'a}gai",
abstract = "Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes. In addition to the antidiabetic properties more attention is paid to their favourable pleiotropic effects independent from the blood glucose lowering such as cardio-, vaso- and renoprotectiv, blood pressure lowering effects, as well as beneficial changes on blood lipid values and hepatic steatosis. These preferential changes prevail in slightly different way when incretin mimetics applied and dipeptidyl peptidase-4 inhibitors, furthermore, prolonged action of peptides metabolised by this enzyme may serve additional benefits in this latter mentioned group. The article overviews the currently known most important pleiotropic effects of incretins from the point of view of cardiorenal risk accompanying type 2 diabetes. Orv. Hetil., 2013, 154, 248-255.",
keywords = "cardio-, dipeptidyl peptidase-4 inhibitors, incretin mimetics, incretins, renoprotection, type 2 diabetes, vaso-",
author = "G. Winkler",
year = "2013",
doi = "10.1556/OH.2013.29553",
language = "Hungarian",
volume = "154",
pages = "248--255",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "7",

}

TY - JOUR

T1 - Inkretinek és inkretinhatású vércukorcsö kkentok pleiotrop tulajdonságai

AU - Winkler, G.

PY - 2013

Y1 - 2013

N2 - Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes. In addition to the antidiabetic properties more attention is paid to their favourable pleiotropic effects independent from the blood glucose lowering such as cardio-, vaso- and renoprotectiv, blood pressure lowering effects, as well as beneficial changes on blood lipid values and hepatic steatosis. These preferential changes prevail in slightly different way when incretin mimetics applied and dipeptidyl peptidase-4 inhibitors, furthermore, prolonged action of peptides metabolised by this enzyme may serve additional benefits in this latter mentioned group. The article overviews the currently known most important pleiotropic effects of incretins from the point of view of cardiorenal risk accompanying type 2 diabetes. Orv. Hetil., 2013, 154, 248-255.

AB - Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes. In addition to the antidiabetic properties more attention is paid to their favourable pleiotropic effects independent from the blood glucose lowering such as cardio-, vaso- and renoprotectiv, blood pressure lowering effects, as well as beneficial changes on blood lipid values and hepatic steatosis. These preferential changes prevail in slightly different way when incretin mimetics applied and dipeptidyl peptidase-4 inhibitors, furthermore, prolonged action of peptides metabolised by this enzyme may serve additional benefits in this latter mentioned group. The article overviews the currently known most important pleiotropic effects of incretins from the point of view of cardiorenal risk accompanying type 2 diabetes. Orv. Hetil., 2013, 154, 248-255.

KW - cardio-

KW - dipeptidyl peptidase-4 inhibitors

KW - incretin mimetics

KW - incretins

KW - renoprotection

KW - type 2 diabetes

KW - vaso-

UR - http://www.scopus.com/inward/record.url?scp=84873639176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873639176&partnerID=8YFLogxK

U2 - 10.1556/OH.2013.29553

DO - 10.1556/OH.2013.29553

M3 - Article

VL - 154

SP - 248

EP - 255

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 7

ER -